Medytox "Focus on Administrative Lawsuit and Strengthen Sales of Other Botox Products"

[Asia Economy Reporter Cho Hyun-ui] As the botulinum toxin product 'Medytoxine' is being withdrawn from the market, attention is focused on the future moves of Medytox, which launched Korea's first domestically developed botox. Since Medytoxine accounts for about 40% of Medytox's annual sales, the company is expected to face significant impact.

A Medytox official stated on the 19th, "We plan to file an administrative lawsuit against the Ministry of Food and Drug Safety's cancellation of the product license while focusing on the dispute with Daewoong Pharmaceutical over the origin of the bacterial strain."

Since the Ministry of Food and Drug Safety already issued a provisional manufacturing and sales suspension order for the product last April, some speculate that Medytox will focus on other botulinum toxin products such as 'Innotox' and 'Coretox' instead of Medytoxine.

However, the company said it intends to directly confront the cancellation of the product license rather than filling the gap left by Medytoxine with other products. A Medytox official said, "The company's basic policy is to contest the cancellation of the product license in an administrative lawsuit, as it is excessive," adding, "We will prevent the cancellation of Medytoxine's product license and continue sales of Innotox and Coretox."

Medytox also plans to devote itself to the 'strain theft' dispute with Daewoong Pharmaceutical. The two companies have been engaged in a truth battle over the origin of the botulinum toxin strain for more than four years. Medytox claims that Daewoong Pharmaceutical stole its botulinum strain, while Daewoong Pharmaceutical insists that it is a different strain from Medytox, maintaining a stalemate.

Medytox has officially filed a complaint with the U.S. International Trade Commission (ITC) against Daewoong Pharmaceutical and its local distributor Evolus. With the ITC scheduled to issue a preliminary ruling on the 6th of next month (local time), there is analysis that the Ministry of Food and Drug Safety's cancellation of the product license could have an impact. The final ruling is expected in early November.

This content was produced with the assistance of AI translation services.